Entrar/Registro  
INICIO ENGLISH
 
Medicina Crítica
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Medicina Crítica >Año 2004, No. 6


Chacón MMA, González CO, Vega ZRE, García LSM, Arias SEA
Factor VII activado recombinante: una opción en el manejo de la hemorragia grave
Rev Asoc Mex Med Crit y Ter Int 2004; 18 (6)

Idioma: Español
Referencias bibliográficas: 60
Paginas: 207-214
Archivo PDF: 88.31 Kb.


Texto completo




RESUMEN

Objetivo: Hacer una revisión de la literatura sobre la utilidad y eficacia del factor VII activado recombinante para el control de la hemorragia grave. Métodos: Se realizó una selección de los artículos más relevantes obtenidos en una búsqueda en MEDLINE, PubMed y OVID de los últimos 10 años en revistas de circulación mundial acerca del tema. Resultados: Se encontraron múltiples informes del uso del factor VII activado recombinante en pacientes con hemorragias graves refractarias a tratamiento quirúrgico o manejo médico que fueron exitosamente controladas con diversas dosis del factor VII activado recombinante. Conclusiones: El factor VII activado recombinante puede representar una opción en el tratamiento de la hemorragia grave de difícil control, aunque es necesaria la realización de estudios controlados para poder definir las indicaciones, usos y dosis del fármaco.


Palabras clave: Factor VII activado recombinante, hemorragia masiva, coagulopatía por dilución.


REFERENCIAS

  1. Drummond J, Petrovitch C. The Massively Bleeding patient. Anesth Clin North Am 2001;19:633-49.

  2. Reiss RF. Hemostatic defects in massive transfusion: rapid diagnosis and management. Am J Crit Care 2000;9: 158-167.

  3. Gubler KD, Gentilello LM. The impact of hypothermia on dilutional coagulopathy. J Trauma 1994;36:847-851.

  4. Poon M. Use of recombinant factor VIIa in hereditary bleeding disorders. Curr Opinion in Hematology 2001;8: 312-318.

  5. Dietrich W, Spannagl M. Caveat against the use of activated recombinant factor VII for intractable bleeding in cardiac surgery. J Cardiothoracic Vasc Anesth 2002;16: 615-616.

  6. Morrisey JH. Tissue factor and factor VII initiation of coagulation. In: Hemostasis and Thrombosis, Basic Principles & Clinical Practice. Ed 4. Edited by Colman RW, HIrish J, Marder VJ, Clowes AW, George JN. Philadelphia: Lippincott Williams & Wilkins; 2001:89-101.

  7. Shapiro AD, Gilchrist GS et al. Prospective, randomized trial of two doses of rFVIIa (Novoseven) in hemophilia patients with inhibitors undergoing surgery. Thromb Haemost 1998;80:773-778.

  8. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Haemost 1998;26: 385-391.

  9. Hoffman M, Monroe DM, Roberts HR. Activated factor VII activates factors IX and X in the surface of activated platelets: thoughts on the mechanism of action of high dose activated factor VII. Blood Coagul Fibrinolysis 1998;9: S61-S65.

  10. Allen GA, Hoffman M, Roberts HR, Monroe DM 3rd. Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. Can J Anaesth 2002;49:S7-14.

  11. Vaný VC, Goleen NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment oh hemophilia A by factor VIIa. Blood 2000;95: 1330-1335.

  12. Novoseven (Coagulation Factor VIIa recombinant): prescription info. Novo nordisk.

  13. Hedner U. Dosing and Monitoring Novoseven treatment. Haemostasis 1996;26:102-108.

  14. Lindley C. Pharmacokinetics and pharmacodynamics of recombinant Factor VIIa. Clin Pharm Ther 1994;55:638-648.

  15. White GC, Rosendal F, Aledort LM, Lusher JM. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and Factor IX of the scientific and standardization committee of the international Society on Thrombosis and Haemostasis. Factor VII and Factor IX subcommittee. Thromb Haemost 2001;85:560.

  16. Brackmann HH, Effenberger E. NovoSeven in immune tolerance therapy. Blood Coagul Fibrinolysis 2000;11: S39-S44.

  17. Allain JP, Frommel D. Antibodies to factor VIII. Patterns of immune response to factor VIII in hemophilia A. Blood 1976;47:973-982.

  18. Scharer I. Recombinant factor VIIa for patients with inhibitors for factor VIII or IX or factor VII deficiency. Hemophilia 1999;5:223-259.

  19. Kessler CM. New products for managing inhibitors to coagulation factors: a focus on recombinant factor VIIa concentrate. Curr Opin Hematol 2000;7:408-413.

  20. Hedner U. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa. Thromb Haemost 1999;82:531-539.

  21. Lusher JM. Acute hemarthroses: the benefits of early versus late treatment with recombinant activated factor VII. Blood Coagul Fibrinolysis 2000;11:S45-S49.

  22. Von Depka M. NovoSeven: mode of action and use in acquired haemophilia. Intensive Care Med 2002;28:S222-7.

  23. Nicolaisen EM. Antigenicity of activated recombinant factor VII followed through nine years of clinical experience. Blood Coagul Fibrinolysis 1998;9:S119-S123.

  24. Kenet G. rFVIIa for profuse bleeding in surgical patients. Bloodline Reviews 2001;1:12-13.

  25. Friederich P, Henny C. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomized trial. Lancet 2003;361:201-205.

  26. Hendricks H, Meijer K. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation. Transplantation 2001;71:402-405.

  27. Ground M. Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a review. Blood Rev 2003;17:S11-S21.

  28. Bernstein DE, Jeffers L, Erhardtsen E. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology 1997;113:1930-1937.

  29. Ejlersen E, Melsen T, Ingerslev J. Recombinant factor VIIa acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol 2001;36:1081-1085.

  30. Sauaia A, Moore FA. Epidemiology of trauma deaths: a reassessment. J Trauma 1995;38:185-93.

  31. Flati G, Andren-Sandberg A. Potentially fatal bleeding in acute pancreatitis: pathophysiology, prevention and treatment. Pancreas 2003;26:8-14.

  32. Krause KR, Howells GA. Hypothermia-induced coagulopathy during hemorrhagic shock. Am Surg 2000;66:348-354.

  33. Gando S, Tedo I, Kubota M. Post-trauma coagulation and fibrinolysis. Crit Care Med 1992;20:594-600.

  34. Cosgriff N, Moore EE. Predicting life-threatening coagulopathy in the massively transfused trauma patient: hypothermia and acidosis revisited. J Trauma 1997;42: 857-862.

  35. Martinowitz U, Kenet G, Lubetski A, Luboshitz J, Segal E. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma. Can J Anaesth 2002;49:S15-S20.

  36. Lockey DJ. Prehospital trauma management. Resuscitation 2001;48:5-15.

  37. Gofrit ON, Leibovici D, Shapira SC. The trimodal death distribution of trauma victims: military experience from Lebanon War. Mil Med 1997;162:24-26.

  38. Martinowitz U, Kenet G, Lubetski A, Luboshitz J, Segal E. Recombinant activated Factor VII adjunctive hemorrhage control in trauma. J Trauma 2001;51:431-9.

  39. O´Neil P, Bluth M, Gloster E. Successful use of recombinant activated Factor VII for Trauma-Associated Hemorrhage in a patient without preexisting coagulopathy. J Trauma 2002;52:400-5.

  40. Lynn M, Jerokhimov I, Popkin C. Early use of recombinant Factor VIIa improves Mean arterial pressure and may decrease mortality in experimental hemorrhagic shock: A pilot study. J Trauma 2002;52:703-7.

  41. Moulton M, Cresswel L. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996;111:1037-46.

  42. Gonzalez-Chon O. Sangrado postoperatorio. En: Complicaciones en la terapia postquirúrgica cardiovascular. Gonzalez-Chon O. (Eds) Manual Moderno 1ra Edición, México, 2002:109-138.

  43. Treatment of excessive bleeding in Jehovah´s witness patients after cardiac surgery with recombinant Factor VIIa (NovoSeven). Anesthesiology 2003;98:1513-1515.

  44. Aldouri M. The use of recombinant factor VIIa in controlling surgical bleeding in non-haemophilic patients. Pathophysiol Haemost Thromb 2002;32:41-46.

  45. von Heymann C, Hotz H, Konertz W, Kox WJ, Spies C. Successful treatment of refractory bleeding with recombinant factor VIIa after redo coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 2002;16:615-6.

  46. Tobias J, Berkenbosch J. Correction of a Coagulopathy Using recombinant actor VII before removal of an Intra-Aortic Balloon Pump. J Cardiothorac Vasc Anesth 2002;16:612-4.

  47. Hendricks H, van der Maaten J. An effective treatment of severe intractable bleeding alter valve repair by one single dose of activated recombinant Factor VII. Cardiovasc Anesth 2001;93:287-9.

  48. González-Chon O, García López S. Complicaciones de la asistencia ventricular. En: Complicaciones en la terapia postquirúrgica cardiovascular. González-Chon O, (Eds). Manual Moderno 1ra Edición, México, 2002:547-564.

  49. Zietkiewicz M, Garlicki M, Domagala J. Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a left ventricular assist device. J Thorac Cardiovasc Surg 2002;123:384-385.

  50. Potapov EV, Pasic M, Bauer M. Activated recombinant factor VII for control of diffuse bleeding after implantation of ventricular assist device. Ann Thorac Surg 2002;74:2 182-2183.

  51. Murkin JM. A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice. Can J Anaesth 2002;49:S21-S26.

  52. Tobias JD, Berkenbosch JW, Russo P. Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Pediatr Crit Care Med 2003;4:49-51.

  53. Hedner U. Recombinant factor VIIa (NovoSeven) as a haemostatic agent. Bloodline Reviews 2001;1:3-4.

  54. Shami VM, Caldwell SH, Hespenheide EE, Arseneau KO, Bickston SJ, Macik BG. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 2003;9:138-43.

  55. Allen GA, Hoffman M, Roberts HR, Monroe DM 3rd. Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. Can J Anaesth 2002;49:S7-S14.

  56. Roberts HR. Recombinant factor VIIa (NovoSeven) and the safety of treatment. Semin Hematol 2001;38:48-50.

  57. Hedner U, Erhardtsen E. Potential role for rFVIIa in transfusion medicine. Transfusion 2002;42:114-24.

  58. Erhardtsen E. Ongoing NovoSeven trials. Intensive Care Med 2002;28:S248-S255.

  59. Egan JR, Lammi A, Schell DN. Recombinant activated factor VII in paediatric cardiac surgery. Intensive Care Med 2003;76:154-157.

  60. Stepinska J, Banaszewski M. Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor Tirofiban. Throm Haemost 2002;87:355-6



>Revistas >Medicina Crítica >Año2004, No. 6
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019